Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN on Wednesday. “Patients who believe that they’re getting access to a ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

A day after the warning landed on semaglutide labels, Novo Nordisk CEO Lars Fruergaard Jørgensen said he is alarmed by the amount of unsafe compounded GLP-1s in the U.S. market, adding that the ...

At a Senate hearing on Sept. 24, Lars Fruergaard Jørgensen of Novo Nordisk, which manufactures Ozempic and Wegovy, faced tough questions about the higher prices in the U.S. compared to Canada and ...

Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Bruger milliarder på ekstremist Bernie Sanders mener slet og ret, at den siddende administration har mistet befolkningens opbakning. Det har den, blandt andet, fordi den bruger milliarder af dollars ...

Trumps handelspolitik kan gå hen og få store konsekvenser for danske virksomheder. En virksomhed på Sjælland fortæller, at de ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...